Reorganization of GlaxoSmithKline's consumer healthcare business will result in the divestment of $800 million worth of over-the-counter products, including its controversial weight loss drug Alli, according to Pharma Times.

The move allows GSK to concentrate on a portfolio of "fast-growing priority brands and the emerging markets" within the division. The divested products are primarily sold in Europe and the U.S. and make up 10% of the company’s total consumer healthcare turnover.

Analgesics such as Solpadeine, the vitamin and supplement product Abtei, the ulcer treatment Zantac (ranitidine) OTC and Alli (orlistat) are some that will be divested.